At a glance
ClinicalIndex Comparison RecordN/ACompleted· 37 enrolled
Drug / intervention
Milnacipran +1 moredrug
Likely dose
Milnacipran 12.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double Blind Placebo Control Trial of Milnacipran for Migraine Pain
In Brief
A clinical study evaluating Milnacipran and Placebo for Chronic Migraine. Completed, enrolled 37 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine if milnacipran taken twice daily is effective in reduction of headache pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJul 2011
Primary CompletionDec 2013
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.0 years ago
Interventions
Milnaciprandrug
titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
Placebodrug
Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down